Scarica l'app Stockscreener
168.40
1.09%
-1.9764
Precedente Chiudi:
$170.38
Aprire:
$170.46
Volume 24 ore:
415.38K
Relative Volume:
0.33
Capitalizzazione di mercato:
$23.14B
Reddito:
$1.96B
Utile/perdita netta:
$-253.24M
Rapporto P/E:
-88.58
EPS:
-1.9012
Flusso di cassa netto:
$94.06M
1 W Prestazione:
+4.69%
1M Prestazione:
+0.30%
6M Prestazione:
+21.89%
1 anno Prestazione:
+31.45%
Intervallo 1D:
$167.33
$173.62
Intervallo di 1 settimana:
$157.43
$173.62
Portata 52W:
$117.27
$183.00
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Confronta NTRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
168.57 | 23.38B | 1.96B | -253.24M | 94.06M | -1.9012 |
|
TMO
Thermo Fisher Scientific Inc
|
540.30 | 205.40B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
210.15 | 151.60B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
625.16 | 50.23B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
139.25 | 40.15B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
201.89 | 34.85B | 15.70B | 1.24B | 2.01B | 6.9036 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
What drives Natera Inc stock priceDividend Yield Trends & Low Cost Portfolio Ideas - earlytimes.in
Chart based exit strategy for Natera Inc.2025 Market WrapUp & Safe Capital Growth Tips - newser.com
Why Natera Inc. stock remains on buy listsJuly 2025 Momentum & Verified Momentum Watchlists - newser.com
Is Natera Inc. building a consolidation base2025 Stock Rankings & Precise Swing Trade Entry Alerts - newser.com
How institutional ownership impacts Natera Inc. stockJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
Natera's Enrollment Surge in EXPAND Trial Could Be a Game Changer for Natera (NTRA) - simplywall.st
Combining machine learning predictions for Natera Inc.Market Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Barclays Keeps Their Buy Rating on Natera (NTRA) - The Globe and Mail
Natera (NTRA): Exploring Valuation as Share Price Pulls Back Despite Strong Growth - simplywall.st
Natera (NTRA): Assessing Valuation Potential as Shares Enter a Quiet Phase - simplywall.st
Is Natera Inc. a candidate for recovery play2025 AllTime Highs & Accurate Trade Setup Notifications - newser.com
Natera Stock (NTRA) Opinions on EXPAND Trial Enrollment and Insider Sales - Quiver Quantitative
Natera CEO Chapman sells $3.7m in stock By Investing.com - Investing.com Australia
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT - BioSpace
Natera enrolls over 1,600 patients in EXPAND trial for fetal testing - Investing.com Nigeria
Insider Sell: Solomon Moshkevich Sells 3,000 Shares of Natera In - GuruFocus
Natera (NTRA) sec. Rabinowitz sells $221k in shares By Investing.com - Investing.com Australia
Natera CFO Brophy sells $403,673 in shares By Investing.com - Investing.com South Africa
Natera CEO Chapman sells $3.7m in stock - Investing.com India
Natera (NTRA) sec. Rabinowitz sells $221k in shares - Investing.com India
Natera CFO Brophy sells $403,673 in shares - Investing.com India
Natera Inc: president Moshkevich sells $479k in stock By Investing.com - Investing.com South Africa
Natera Inc: president Moshkevich sells $479k in stock - Investing.com
Natera, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Why Natera’s Stock is Gaining Attention - TipRanks
Natera (NTRA) Achieves Key Enrollment Milestone in EXPAND Trial - GuruFocus
Natera enrolls over 1,600 patients in EXPAND trial for fetal testing By Investing.com - Investing.com South Africa
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer - BioSpace
Natera’s ctDNA test outperforms standard markers in testicular cancer By Investing.com - Investing.com Nigeria
Natera’s ctDNA test outperforms standard markers in testicular cancer - Investing.com India
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - BioSpace
Natera, Inc. (NASDAQ:NTRA) Given Average Rating of "Buy" by Brokerages - MarketBeat
GAMMA Investing LLC Acquires 411 Shares of Natera, Inc. $NTRA - Defense World
Natera's president sells shares worth $117,861 - MSN
Natera’s Signatera test shows strong results for uterine cancer monitoring By Investing.com - Investing.com Canada
Natera’s Signatera test shows strong results for uterine cancer monitoring - Investing.com
SWS Partners Reduces Stake in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. (NTRA) Stock Analysis: Evaluating the 18.92% Upside Potential in Healthcare Diagnostics - DirectorsTalk Interviews
Natera, Inc. (NTRA) Stock Analysis: 18.92% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.61%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):